Genelux
Market cap $96.1M 48.1M shares (10-Q, Nov 11, 2026) × $2.00 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- Olvi-Vec NSCLC Ph2 interim2026Olvi-Vec NSCLC Ph2 interim, 2026, notable
- Olvi-Vec SCLC Ph2 interim2026Olvi-Vec SCLC Ph2 interim, 2026, notable
- Olvi-Vec OnPrime Ph3 topline2H 2026Olvi-Vec OnPrime Ph3 topline, 2H 2026, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Technology platforms
CHOICE
Proprietary selection technology and discovery and development platform for oncolytic vaccinia virus (VACV) immunotherapeutic candidates; enables development of library of isolated and engineered oncolytic VACV candidates for multiple tumor types in monotherapy and combination settings via regional, local, and systemic delivery routes.
Capital (as filed)
- Cash
- $9.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $1.0M Sep 30, 2026
- Operating cash flow
- −$5.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $10.4M cash, runway into the first quarter of 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-17 UPDATE: Genelux (GNLX) - Six Weeks, Fifteen Million, One Coin 🔒 Paid
- 2026-08-14 UPDATE: Genelux (GNLX) - The Fuel Gauge Meets the Catalyst 🔒 Paid
- 2026-07-15 Genelux Corporation (GNLX) — Scientific Deep Dive for Olvi-Vec and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Genelux, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-07-15 Watch Genelux Corporation (GNLX) — Scientific Deep Dive for Olvi-Vec and Pipeline Products The science is legitimate and the randomized pivotal genuinely de-risks the single-arm data, but with runway ending at the 2H-2026 readout, a going-concern warning, certain dilution, and a modality that has never commercialized, this is a binary event trade to watch, not own.
- 2026-08-14 Watch UPDATE: Genelux (GNLX) - The Fuel Gauge Meets the Catalyst Q2 burn accelerated to $9.6M against $18.7M cash, the ATM is barely functioning, and the runway-to-readout squeeze tightened, but the Phase 3 remains on track for 2H 2026 and the science is unchanged.
- 2026-11-17 Watch UPDATE: Genelux (GNLX) - Six Weeks, Fifteen Million, One Coin With share count up 26% YTD, accrued trial bills doubled, working capital cushion thin, and OnPrime topline due within weeks, waiting for the data and the financing that follows is more defensible than guessing ahead of the print.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (12)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseGenelux Corporation Reports Third Quarter Financial Results and Provides Business Updates→ BD updateSummary on the 10-Q
- Nov 16, 202610-QQuarterly report→ BD updateThe Q3 10-Q reveals a ~$5.1M post-quarter ATM dump at ~$2/share that roughly doubled the ATM's total haul from inception, the Chief Scientific Officer adopted a sell plan for up to 98,000 shares, and accrued R&D liabilities surged to $8.1M — the runway-meets-binary squeeze is now tighter than ever, and the smart-money signals are pointing the wrong way with the Phase 3 readout still unscheduled within "2H 2026."
- Sep 9, 2026ReleaseGenelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ImmunochemotherapyBD extracted 1 program update from this document → GNLX pipeline
- Aug 13, 2026ReleaseGenelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- Aug 13, 202610-QQuarterly report
- Jun 22, 20268-KCurrent report: shareholder vote
- May 7, 202610-QQuarterly report
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Mar 19, 20268-KCurrent report: material agreement
- Mar 19, 2026424B5Prospectus supplement (offering)
- Mar 19, 202610-KAnnual report
3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 4, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026ARSAnnual report to shareholders
- Mar 19, 2026S-8Employee plan registration